4.7 Article

Hydralazine attenuates renal inflammation in diabetic rats with ischemia/reperfusion acute kidney injury

期刊

EUROPEAN JOURNAL OF PHARMACOLOGY
卷 910, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.ejphar.2021.174468

关键词

Diabetic; Acute kidney injury; Advanced glycation end products; Receptor for advanced glycation endproducts; Rat mesangial cells; Hydralazine

资金

  1. Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

向作者/读者索取更多资源

The research suggests that Hydralazine has the potential to reduce oxidative stress and inflammation in AGEs-induced kidney injury in diabetic patients, showing promising therapeutic effects.
Acute kidney injury (AKI) is one of the major complications with increased oxidative stress and inflammation in diabetic patients. Hyperglycemia stimulates the formation of advanced glycation end products (AGEs). However, hyperglycemia directly triggers the interaction between AGEs and transmembrane AGEs receptors (RAGE), which enhances oxidative stress and increases the production of inflammatory substances. Therefore, diabetes plays a pivotal role in kidney injury. Hydralazine, a vasodilator and antihypertensive drug, was found to have the ability to reduce ROS, oxidative stress, and inflammation. We applied Hydralazine co-culture with AGEs in rat mesangial cells (RMC) and to renal ischemia/reperfusion(I/R) injury models in streptozotocin-induced diabetic rats. Hydralazine significantly decreased AGEs-induced RAGE, iNOS, and COX-2 expressions in RMC. Compared to the diabetic with AKI group, hydralazine decreased inflammation-related protein, and JAK2, STAT3 signaling in rat kidney tissue. Our studies indicate that Hydralazine has the potential to become a beneficial drug in the treatment of diabetic acute kidney injury.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据